<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-7-132</article-id><article-id pub-id-type="pmid">17640379</article-id><article-id pub-id-type="doi">10.1186/1471-2407-7-132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Origin and distribution of the BRCA2-8765delAG mutation in breast cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Palomba</surname><given-names>Grazia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>graziap68@yahoo.it</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Cossu</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>cossu@uniss.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Friedman</surname><given-names>Eitan</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>Eitan.Friedman@sheba.health.gov.il</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Budroni</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mariobudroni@tiscalinet.it</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Farris</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>afarris@uniss.it</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Contu</surname><given-names>Antonio</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>oncomedss@tiscali.it</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Pisano</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>marina.pisano@icb.cnr.it</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Baldinu</surname><given-names>Paola</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pbaldinu@yahoo.it</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Sini</surname><given-names>Maria C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mc.sini@tiscali.it</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Tanda</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>tandaf@uniss.it</email></contrib><contrib id="A11" corresp="yes" contrib-type="author"><name><surname>Palmieri</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gpalmieri@yahoo.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Istituto di Chimica Biomolecolare-Consiglio Nazionale Ricerche, Sassari, Italy</aff><aff id="I2"><label>2</label>Servizio di Anatomia Patologica, Azienda USL1, Sassari, Italy</aff><aff id="I3"><label>3</label>Chaim Sheba Medical Center, Tel-Hashomer, Israel</aff><aff id="I4"><label>4</label>Centro Epidemiologico Multizonale, Azienda USL1, Sassari, Italy</aff><aff id="I5"><label>5</label>Universit&#x000e0; degli Studi di Sassari, Italy</aff><aff id="I6"><label>6</label>Ospedale Civile, Azienda USL1, Sassari, Italy</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>19</day><month>7</month><year>2007</year></pub-date><volume>7</volume><fpage>132</fpage><lpage>132</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/132"/><history><date date-type="received"><day>2</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Palomba et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Palomba et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Palomba Grazia graziap68@yahoo.it </dc:author><dc:title> Origin and distribution of the BRCA2-8765delAG mutation in breast cancer </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cancer 7(1): 132-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2007)7:1&#x0003c;132&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The <italic>BRCA2</italic>-8765delAG mutation was firstly described in breast cancer families from French-Canadian and Jewish-Yemenite populations; it was then reported as a founder mutation in Sardinian families. We evaluated both the prevalence of the <italic>BRCA2</italic>-8765delAG variant in Sardinia and the putative existence of a common ancestral origin through a haplotype analysis of breast cancer family members carrying such a mutation.</p></sec><sec sec-type="methods"><title>Methods</title><p>Eight polymorphic microsatellite markers (D13S1250, centromeric, to D13S267, telomeric) spanning the <italic>BRCA2 </italic>gene locus were used for the haplotype analysis. Screening for the 8765delAG mutation was performed by PCR-based amplification of <italic>BRCA2</italic>-exon 20, followed by automated sequencing.</p></sec><sec><title>Results</title><p>Among families with high recurrence of breast cancer (&#x02265; 3 cases in first-degree relatives), those from North Sardinia shared the same haplotype whereas the families from French Canadian and Jewish-Yemenite populations presented distinct genetic assets at the BRCA2 locus. Screening for the <italic>BRCA2</italic>-8765delAG variant among unselected and consecutively-collected breast cancer patients originating from the entire Sardinia revealed that such a mutation is present in the northern part of the island only [9/648 (1.4%) among cases from North Sardinia versus 0/493 among cases from South Sardinia].</p></sec><sec><title>Conclusion</title><p>The <italic>BRCA2</italic>-8765delAG has an independent origin in geographically and ethnically distinct populations, acting as a founder mutation in North but not in South Sardinia. Since <italic>BRCA2</italic>-8765delAG occurs within a triplet repeat sequence of AGAGAG, our study further confirmed the existence of a mutational hot-spot at this genomic position (additional genetic factors within each single population might be involved in generating such a mutation).</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Breast Cancer (BC) is the most common malignancy among women in industrialized countries. Germline mutations in BRCA1 (MIM 113705) and BRCA2 (MIM 600185) genes account for cancer predisposition in majority of families with BC recurrence. Positive family history is indeed recognized as a high risk factor for developing the disease; about 10% of all breast cancers arise in individuals carrying a germline mutation in one of such two genes [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>According to the Breast Cancer Information Core (BIC) database [<xref ref-type="bibr" rid="B2">2</xref>], the majority of germline alterations identified in <italic>BRCA1 </italic>and <italic>BRCA2 </italic>is unique (57% and 63%, respectively); the remaining ones are recurrent founder mutations which have been described in different ethnic groups and populations [<xref ref-type="bibr" rid="B3">3</xref>]. Mutations that are observed repeatedly associated with a common haplotype are likely to have descended from a common ancestor, and are referred to as "founder mutations". Although at different rates, <italic>BRCA1 </italic>and <italic>BRCA2 </italic>founder mutation have been detected in genetically homogeneous populations, such as the Icelanders [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>], the Ashkenazi Jews [<xref ref-type="bibr" rid="B6">6</xref>], the Finns [<xref ref-type="bibr" rid="B7">7</xref>], and the French-Canadians [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The <italic>BRCA2</italic>-8765delAG mutation was described as a founder mutation in Jewish-Yemenite families [<xref ref-type="bibr" rid="B9">9</xref>], as well as in French-Canadian families [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Our group has also described the <italic>BRCA2</italic>-8765delAG variant as a founder mutation in about 12% breast cancer families originating from different villages of North Sardinia [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Although the age of the BRCA2-8765delAG variant has not yet been determined, this mutation appears on an ancient haplotype [<xref ref-type="bibr" rid="B11">11</xref>]. Moreover, the BRCA2-8765delAG mutation has been demonstrated to be present in all affected individuals from the four (57%) out of seven breast cancer families who shared an identical-by-descent haplotype within North Sardinia [<xref ref-type="bibr" rid="B11">11</xref>]. A previous study has also reported the comparison of haplotypes of French Canadians and Yemenite Jewish mutation carriers, indicating the independent origins of carriers of the BRCA2-8765delAG mutation in these two populations [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Overall, this mutation has been reported forty-two times into the Breast Cancer Information Core database, and it has been found to occur in populations throughout Europe and North America. No information is however available about the question whether <italic>BRCA2</italic>-8765delAG may be an ancient or common mutation in Mediterranean area (which Sardinia and Israel belong to). In this sense, we performed a haplotype analysis among breast cancer families carrying the BRCA2-8765delAG mutation from Sardinian and Jewish-Yemenite populations (also referring to data among French-Canadian families) as well as definitely determined the prevalence of such a variant among unselected breast cancer cases originating from the entire Sardinia island.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and families</title><p>Families containing probands with histologically-proven diagnosis of breast cancer and carrying the <italic>BRCA2</italic>-8765delAG mutation were recruited from clinics at the University of Sassari and Azienda Unit&#x000e0; Sanitaria Locale 1 of Sassari (which represent the principal medical institutions accounting for cancer patients from the central and northern parts of the island) and from familial cancer genetics clinics in Israel; DNA samples of two French-Canadian families carrying the BRCA2-8765delAG were previously provided by P. Tonin. Sardinian families were unrelated since they did not present any common ancestor after evaluation of pedigrees up to 1700.</p><p>All information regarding the recurrence of cancers in family, age at cancer diagnosis, and age at death or current age were collected after obtaining a written informed consent. Most of the information were verified by analysis of the Hospital records; all cancer diagnoses were confirmed by pathology reports. After the patients were informed about the aims and limits of the study, blood samples were obtained with their written consent. DNA samples were collected from at least one affected member of each family.</p><p>Appropriate institutional informed consent guidelines were followed for all recruited patients. The study was reviewed and approved by the ethical review boards of both participating institutions (University and Azienda USL1 of Sassari).</p></sec><sec><title>DNA analysis</title><p>Haplotype analysis was performed using nine polymorphic microsatellite repeat markers, three intragenic (D13S260, D13S1701, and D13S171) and the remaining flanking the <italic>BRCA2 </italic>gene (D13S1250, D13S1299, D13S1246, D13S289, D13S310 and D13S267). For these markers, heterozygosity varied from 69% to 82%; primer sequences and PCR conditions for amplification were as indicated into the Human Genome Database [<xref ref-type="bibr" rid="B15">15</xref>]. Marker loci were ordered as in Ensembl map [<xref ref-type="bibr" rid="B16">16</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). Alleles were numbered according to size for each microsatellite marker.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Results from haplotype analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center"><bold>Cromo some</bold></td><td align="center"><bold>Ensembl Map (Mb)</bold></td><td align="center"><bold>Marker</bold></td><td align="center"><bold>North Sardinia</bold></td><td align="center" colspan="2"><bold>Jewish-Yemenite</bold></td><td align="center" colspan="2"><bold>French-Canadian</bold></td></tr><tr><td></td><td></td><td></td><td></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td align="center">Fam.1</td><td align="center">Fam.2</td><td align="center">Fam.1</td><td align="center">Fam.2</td></tr></thead><tbody><tr><td align="center">13q12.3</td><td align="center">27.80</td><td align="center">D13S1250</td><td align="center">8</td><td align="center">8</td><td align="center">5</td><td align="center">n.t.</td><td align="center">n.t.</td></tr><tr><td></td><td align="center">29.45</td><td align="center">D13S1299</td><td align="center">3</td><td align="center">3</td><td align="center">2</td><td align="center">n.t.</td><td align="center">n.t.</td></tr><tr><td></td><td align="center">30.00</td><td align="center">D13S1246</td><td align="center">5</td><td align="center">4&#x02013;8</td><td align="center">1</td><td align="center">n.t.</td><td align="center">n.t.</td></tr><tr><td></td><td align="center">30.15</td><td align="center">D13S289</td><td align="center">3</td><td align="center">3</td><td align="center">3</td><td align="center">n.t.</td><td align="center">n.t.</td></tr><tr><td align="center">13q13.1</td><td align="center">31.35</td><td align="center">D13S260</td><td align="center">8</td><td align="center">8</td><td align="center">3</td><td align="center">7</td><td align="center">7</td></tr><tr><td></td><td align="center"><bold>31.80</bold></td><td align="center"><bold>BRCA2</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center">32.05</td><td align="center">D13S1701</td><td align="center">6</td><td align="center">5</td><td align="center">5</td><td align="center">8</td><td align="center">8</td></tr><tr><td></td><td align="center">32.15</td><td align="center">D13S171</td><td align="center">10</td><td align="center">3&#x02013;4</td><td align="center">4</td><td align="center">4&#x02013;11</td><td align="center">4&#x02013;6</td></tr><tr><td></td><td align="center">32.65</td><td align="center">D13S310</td><td align="center">5</td><td align="center">5</td><td align="center">3</td><td align="center">n.t.</td><td align="center">n.t.</td></tr><tr><td align="center">13q13.2</td><td align="center">33.15</td><td align="center">D13S267</td><td align="center">2</td><td align="center">5&#x02013;8</td><td align="center">8</td><td align="center">n.t.</td><td align="center">n.t.</td></tr></tbody></table><table-wrap-foot><p>The genomic position of the <italic>BRCA2 </italic>gene is indicated. n.t., not tested</p></table-wrap-foot></table-wrap><p>Briefly, DNA samples from 32 individuals in 7 families (three from North-Sardinia, two from Israel and two from Canada) carrying the <italic>BRCA2</italic>-8765delAG mutation were genotyped. All primers labelled with fluorescein derivatives (5'-6-FAM, or 5'-HEX) were from MWG-Biotech (Ebersberg, Germany). For each sample, 50 ng of genomic DNA was amplified using 200 &#x003bc;mol/L deoxynucleotide triphosphates, 0.4 &#x003bc;mol/L primers, 1.5 mmol/L MgCl<sub>2</sub>, and 0.625 units of Taq DNA Polymerase, according to standard PCR procedures. Microsatellite genotyping was carried out on an automated ABIPRISM 3100 DNA sequencer (Applied Biosystems, Foster City, CA) and PCR fragments were analysed using the Genescan 3.7.1<sup>&#x000ae; </sup>software.</p><p>Genomic DNA for mutational screening of 1,141 unselected breast cancer patients was isolated from both peripheral blood samples (N = 691) and archival paraffin-embedded tissues (N = 450), using standardized procedures. To avoid any bias, paraffin-embedded normal tissues from breast cancer patients were consecutively collected; all cases were thus included regardless of age at diagnosis, family history status, and disease features. Sardinian origin was ascertained in all cases through genealogical studies. For mutation screening, exon 20 of the <italic>BRCA2 </italic>gene was amplified and PCR products were directly sequenced using an automated fluorescence-cycle sequencer.</p></sec></sec><sec><title>Results</title><p>For haplotype analysis, breast cancer families carrying the <italic>BRCA2</italic>-8765delAG mutation and originating from North-Sardinia (N = 3), Israel (N = 2), and French area of Canada (N = 2) were included into the study. Among the seven families, 32 members, including 16 probands with histologically-proven diagnosis of breast cancer, were genotyped with markers spanning the <italic>BRCA2 </italic>locus at chromosome 13q12-q13. All families had at least three individuals diagnosed with breast cancer in first-degree relatives and presence of the <italic>BRCA2</italic>-8765delAG mutation in all family probands from the three populations was confirmed by direct sequencing (Figure <xref ref-type="fig" rid="F1">1</xref>). The <italic>BRCA2</italic>-8765delAG mutation was absent in blood DNA from 103 unrelated healthy individuals (corresponding to 206 chromosomes), originating from the same geographical area and used as normal controls. Pedigrees of analyzed BC families from North Sardinia and Israel are shown in Figure <xref ref-type="fig" rid="F2">2</xref>. For both French-Canadian families, one proband along with the two parents from each family was analyzed.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold><italic>BRCA2</italic>-8765delAG mutation</bold>. Electropherogram shows the nucleotide sequence at the genomic level in a positive breast cancer patient. The wild-type (WT) and the mutant (Mut) nucleotide sequences have been reported (the deleted AG has been boxed). Arrow indicates the mutation position.</p></caption><graphic xlink:href="1471-2407-7-132-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Pedigrees of analyzed <italic>BRCA2</italic>-8765delAG positive families from Sardinian and Jewish-Yemenite populations</bold>. Arrows indicate the family members who underwent haplotype analysis. S and J-Y, Sardinian and Jewish-Yemenite families (respectively).</p></caption><graphic xlink:href="1471-2407-7-132-2"/></fig><p>In Sardinian families, an identical haplotype was inferred by genotyping all affected family members carrying the <italic>BRCA2</italic>-8765delAG mutation with marker loci D13S1250 to D13S267 (centromeric to telomeric) (Table <xref ref-type="table" rid="T1">1</xref>). This unique haplotype (8-3-5-3-8-10-5-2) among BC families from North Sardinia was not found in 80 control chromosomes from the same geographical area. Surprisingly, the two Jewish-Yemenite families presented two different haplotypes; one of them only, Fam.1, shared majority of the alleles (5/9; 56%) observed into the Sardinian series (Table <xref ref-type="table" rid="T1">1</xref>). For the remaining French-Canadian families, haplotype analysis was carried out for the three closely flanking BRCA2 marker loci only (D13S260, D13S1701, and D13S171), due to the low amount of the available germline DNA. Although with such a limited number of markers, the inferred haplotype of the French-Canadian cases was consistent in families from the same population but different when compared with familial cases from both the Sardinian and Jewish-Yemenite populations (Table <xref ref-type="table" rid="T1">1</xref>). Overall, the <italic>BRCA2</italic>-8765delAG mutation was found to occur associated with distinct haplotypes into the three analyzed populations.</p><p>To evaluate the prevalence of BRCA2-8765delAG in breast cancer cases across the entire Sardinia, we screened genomic DNA obtained from both peripheral blood and paraffin-embedded normal tissues (see Methods) of 1,141 unselected and consecutively-collected BC patients originating from either the northern (N = 648) or southern (N = 493) part of the island. The 2-bp deletion in exon 20 of the <italic>BRCA2 </italic>gene was detected by direct automated sequencing of the correspondent PCR products (Figure <xref ref-type="fig" rid="F1">1</xref>). The <italic>BRCA2</italic>-8765delAG mutation was found in 9/648 (1.4%) cases from North Sardinia and 0/493 cases from South Sardinia (Figure <xref ref-type="fig" rid="F3">3</xref>). Interestingly, all the nine breast cancer patients found positive to <italic>BRCA2</italic>-8765delAG were from families with at least three affected members in first-degree relatives [whereas familial recurrence of breast cancer was observed in 87 (13.5%) out of 644 mutation-negative patients, whose information on family history for cancer was available], further confirming that occurrence of the BRCA2 mutations is strictly associated with the presence of a higher familial recurrence of the disease.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Distribution of breast cancer patients carrying the <italic>BRCA2</italic>-8765delAG mutation</bold>. Geographical areas of the island from which patients were collected are indicated (the two colours correspond to the northern and southern part of the island). Dots indicate the origin of patients presenting the <italic>BRCA2</italic>-8765delAG mutation.</p></caption><graphic xlink:href="1471-2407-7-132-3"/></fig></sec><sec><title>Discussion</title><p>The unique haplotype common to all three breast cancer families from North Sardinia indicated the <italic>BRCA2</italic>-8765delAG as a founder mutation in this geographical area. Haplotype analysis revealed that Sardinian mutation carriers shared majority of allele markers with only one of the two Jewish-Yemenite families; the remaining Jewish-Yemenite family and the French-Canadian families did not present the same genotypic asset (see Table <xref ref-type="table" rid="T1">1</xref>).</p><p>In the BIC database [<xref ref-type="bibr" rid="B2">2</xref>], the <italic>BRCA2</italic>-8765delAG variant is a recurrent mutation occurring in a AG-rich sequence of the <italic>BRCA2 </italic>gene. Recombination events or marker mutations could theoretically account for haplotype divergence from a single, original haplotype but seem not to be likely explanations here. Indeed, our results indicate that carriers of the BRCA2-8765delAG variant may have an independent origin and, although already suggested for French-Canadians and Yemenite-Jews [<xref ref-type="bibr" rid="B14">14</xref>], allow to exclude the presence of a common ancestor in Mediterranean area also. Therefore, one could hypothesize the existence of a mutational hot-spot at this genomic position within the <italic>BRCA2 </italic>gene locus. Since the mutation is an AG-deletion in a stretch of AGAGAG, the chance of recurrent mutations at this site might be higher than that in a site having a single AG. On this regard, differences into the genetic background may be due to a replication slippage resulting in the loss of repeat units during meiosis or recombination events (putatively dependent on the simultaneous presence of additional genetic factors or, more in general, favouring genomic backgrounds). As a confirmation of this hypothesis, other authors have described different nucleotide deletions at this genomic level among families with breast and/or ovarian cancer [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Nevertheless, one should also take into account that a deletion of AG in a triplet repeat sequence of AGAGAG does not allow to accurately determine whether the mutations that occur in the different populations are really identical.</p><p>Considering the incidence of the <italic>BRCA2</italic>-8765delAG variant among the unselected patients from the Sardinian population, our extensive screening clearly indicated that such a mutation is recurrent in North Sardinia (confirming its role as founder mutation in this part of the island [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]) but absent in South Sardinia. The Sardinia island has a relatively small, isolated, and genetically homogeneous population with a high rate of inbreeding; several founder effects have been already demonstrated for monogenic or complex diseases in this population [<xref ref-type="bibr" rid="B19">19</xref>]. For breast cancer, heterogeneous genetic backgrounds seem to instead account for such deep differences into the <italic>BRCA2 </italic>gene involvement. As we recently demonstrated for malignant melanoma [<xref ref-type="bibr" rid="B20">20</xref>], these findings further support the hypothesis that patients' origin (even in so close geographical areas) may determine different susceptibility roles of the candidate cancer genes and, for the same gene, different mutation rates might be observed.</p><p>As we previously described [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>], the prevalence of the <italic>BRCA2</italic>-8765delAG mutation in breast cancer families was lower than that of other <italic>BRCA1-2 </italic>founder mutations observed in different genetically-homogeneous populations (three BRCA1 and a single <italic>BRCA2 </italic>founder mutations account for vast majority of breast cancer families among Ashkenazi Jews [<xref ref-type="bibr" rid="B21">21</xref>] and Icelanders [<xref ref-type="bibr" rid="B22">22</xref>], respectively). Considering the screening of consecutively-collected unselected BC cases, the fraction of 1.4% <italic>BRCA2 </italic>mutation carriers is analogously low in breast cancer patients from North Sardinia (again, a quite sharp contrast between our frequencies and those observed in unselected cases from either Ashkenazi Jewish [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>] and Icelandic [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>] populations was observed).</p><p>In conclusion, our study allowed to assess that <italic>BRCA2</italic>-8765delAG, arising in conjunction with several and clearly distinct genetic haplotypes, may be generated in an independent manner and at a frequency higher than other <italic>BRCA2 </italic>mutations among breast cancer families world-wide. A clinically relevant implication is that such a recurrent mutation should be included in targeted <italic>BRCA2 </italic>mutation screening panels in any population, irrespective of ethnic origin. Finally, our heterogeneous data from the screening of breast cancer patients belonging to a so-recognized genetically-homogeneous population, can be further considered as indicative that both role and mutation prevalence of any candidate cancer gene needs to be evaluated in each geographical area.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>GRP participated in the design of the study and performed the molecular analyses. ACOS performed the data management. EF participated in the families' collection. MB participated in the analysis and interpretation of data. AF participated in the patients' collection. ACON participated in the patients' collection. MP performed some haplotype analyses. PB performed some screening analyses. MCS performed some screening analyses. FT participated in the design of the study. GIP conceived of the study and drafted the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/132/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Authors are grateful to patients and families for their important contribution to this study. Work was funded by Regione Autonoma della Sardegna, Ricerca Finalizzata Ministero della Salute, Associazione Italiana Ricerca sul Cancro, and Associazione UMANA Onlus.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Stratton</surname><given-names>M</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Goldgar</surname><given-names>D</given-names></name><name><surname>Devilee</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Lenoir</surname><given-names>G</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name></person-group><article-title>Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families</article-title><source>Am J Hum Genet</source><year>1998</year><volume>62</volume><fpage>676</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">9497246</pub-id><pub-id pub-id-type="doi">10.1086/301749</pub-id></citation></ref><ref id="B2"><citation citation-type="other"><article-title>Breast Cancer Information Core (BIC)</article-title><ext-link ext-link-type="uri" xlink:href="http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic"/></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>C</given-names></name><name><surname>Masiello</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>JF</given-names></name><collab>The BIC Consortium</collab><name><surname>Brody</surname><given-names>LC</given-names></name></person-group><article-title>The Breast Cancer Information Core: Database Design, Structure, and Scope</article-title><source>Hum Mut</source><year>2000</year><volume>16</volume><fpage>123</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10923033</pub-id><pub-id pub-id-type="doi">10.1002/1098-1004(200008)16:2&#x0003c;123::AID-HUMU4&#x0003e;3.0.CO;2-Y</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Johannesdottir</surname><given-names>G</given-names></name><name><surname>Arason</surname><given-names>A</given-names></name><name><surname>Bergthorsson</surname><given-names>JT</given-names></name><name><surname>Ingvarsson</surname><given-names>S</given-names></name><name><surname>Egilsson</surname><given-names>V</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name></person-group><article-title>Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype</article-title><source>Am J Hum Genet</source><year>1996</year><volume>58</volume><fpage>749</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">8644738</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Hartge</surname><given-names>P</given-names></name><name><surname>Olafsdottir</surname><given-names>GH</given-names></name><name><surname>Sigvaldason</surname><given-names>H</given-names></name><name><surname>Tryggvadottir</surname><given-names>L</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Tulinius</surname><given-names>H</given-names></name><name><surname>Eyfjord</surname><given-names>JE</given-names></name></person-group><article-title>Population-based study of risk of breast cancer in carriers of BRCA2 mutation</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1337</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9802270</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)03300-5</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roa</surname><given-names>BB</given-names></name><name><surname>Boyd</surname><given-names>AA</given-names></name><name><surname>Volcik</surname><given-names>K</given-names></name><name><surname>Richards</surname><given-names>CS</given-names></name></person-group><article-title>Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2</article-title><source>Nat Genet</source><year>1996</year><volume>14</volume><fpage>185</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8841191</pub-id><pub-id pub-id-type="doi">10.1038/ng1096-185</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vehmanen</surname><given-names>P</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Eerola</surname><given-names>H</given-names></name><name><surname>McClure</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>B</given-names></name><name><surname>Sarantaus</surname><given-names>L</given-names></name><name><surname>Kainu</surname><given-names>T</given-names></name><name><surname>Syrjakoski</surname><given-names>K</given-names></name><name><surname>Pyrhonen</surname><given-names>S</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name></person-group><article-title>Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes</article-title><source>Hum Mol Genet</source><year>1997</year><volume>6</volume><fpage>2309</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">9361038</pub-id><pub-id pub-id-type="doi">10.1093/hmg/6.13.2309</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tonin</surname><given-names>PN</given-names></name><name><surname>Mes-Masson</surname><given-names>AM</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Mahon</surname><given-names>M</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Cole</surname><given-names>DE</given-names></name><name><surname>Provencher</surname><given-names>D</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name></person-group><article-title>Founder <italic>BRCA1 </italic>and <italic>BRCA2 </italic>mutations in French Canadian breast and ovarian cancer families</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>1341</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">9792861</pub-id><pub-id pub-id-type="doi">10.1086/302099</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lerer</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Peretz</surname><given-names>T</given-names></name><name><surname>Sagi</surname><given-names>M</given-names></name><name><surname>Kaduri</surname><given-names>L</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Stadler</surname><given-names>J</given-names></name><name><surname>Gutman</surname><given-names>H</given-names></name><name><surname>Abeliovich</surname><given-names>D</given-names></name></person-group><article-title>The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction</article-title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>272</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9634522</pub-id><pub-id pub-id-type="doi">10.1086/301924</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phelan</surname><given-names>CM</given-names></name><name><surname>Lancaster</surname><given-names>JM</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Gumbs</surname><given-names>C</given-names></name><name><surname>Cochran</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Perret</surname><given-names>C</given-names></name><name><surname>Moslehi</surname><given-names>R</given-names></name><name><surname>Dion</surname><given-names>F</given-names></name></person-group><article-title>Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>120</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">8673090</pub-id><pub-id pub-id-type="doi">10.1038/ng0596-120</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pisano</surname><given-names>M</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Persico</surname><given-names>I</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Angius</surname><given-names>A</given-names></name><name><surname>Casu</surname><given-names>G</given-names></name><name><surname>Palomba</surname><given-names>G</given-names></name><name><surname>Sarobba</surname><given-names>MG</given-names></name><name><surname>Rocca</surname><given-names>PC</given-names></name><name><surname>Dedola</surname><given-names>MF</given-names></name><name><surname>Olmeo</surname><given-names>N</given-names></name><name><surname>Pasca</surname><given-names>A</given-names></name><name><surname>Budroni</surname><given-names>M</given-names></name><name><surname>Marras</surname><given-names>V</given-names></name><name><surname>Pisano</surname><given-names>A</given-names></name><name><surname>Farris</surname><given-names>A</given-names></name><name><surname>Massarelli</surname><given-names>G</given-names></name><name><surname>Pirastu</surname><given-names>M</given-names></name><name><surname>Tanda</surname><given-names>F</given-names></name></person-group><article-title>Identification of a founder BRCA2 mutation in Sardinia</article-title><source>Brit J Cancer</source><year>2000</year><volume>82</volume><fpage>553</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10682665</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.1999.0963</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname><given-names>G</given-names></name><name><surname>Palomba</surname><given-names>G</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Pisano</surname><given-names>M</given-names></name><name><surname>Dedola</surname><given-names>MF</given-names></name><name><surname>Sarobba</surname><given-names>MG</given-names></name><name><surname>Farris</surname><given-names>A</given-names></name><name><surname>Olmeo</surname><given-names>N</given-names></name><name><surname>Contu</surname><given-names>A</given-names></name><name><surname>Pasca</surname><given-names>A</given-names></name><name><surname>Satta</surname><given-names>MP</given-names></name><name><surname>Persico</surname><given-names>I</given-names></name><name><surname>Carboni</surname><given-names>AA</given-names></name><name><surname>Cossu-Rocca</surname><given-names>P</given-names></name><name><surname>Contini</surname><given-names>M</given-names></name><name><surname>Mangion</surname><given-names>J</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Tanda</surname><given-names>F</given-names></name></person-group><article-title>BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling</article-title><source>Ann Oncol</source><year>2002</year><volume>13</volume><fpage>1899</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">12453858</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdf326</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palomba</surname><given-names>G</given-names></name><name><surname>Pisano</surname><given-names>M</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Budroni</surname><given-names>M</given-names></name><name><surname>Dedola</surname><given-names>MF</given-names></name><name><surname>Farris</surname><given-names>A</given-names></name><name><surname>Contu</surname><given-names>A</given-names></name><name><surname>Baldinu</surname><given-names>P</given-names></name><name><surname>Tanda</surname><given-names>F</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name></person-group><article-title>Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital-based screening</article-title><source>Cancer</source><year>2005</year><volume>104</volume><fpage>1172</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16047344</pub-id><pub-id pub-id-type="doi">10.1002/cncr.21298</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>AP</given-names></name><name><surname>Abelovich</surname><given-names>D</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>Lambert</surname><given-names>JA</given-names></name><name><surname>Frappier</surname><given-names>D</given-names></name><name><surname>Provencher</surname><given-names>D</given-names></name><name><surname>Robidoux</surname><given-names>A</given-names></name><name><surname>Peretz</surname><given-names>T</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Mes-Masson</surname><given-names>A-M</given-names></name><name><surname>Foulkes</surname><given-names>WF</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>TM</given-names></name><name><surname>Tonin</surname><given-names>PN</given-names></name></person-group><article-title>Haplotype analysis of BRCA2 8765delAG Mutation Carriers in French Canadian and Yeminite Jewish Hereditary Breast Cancer Families</article-title><source>Hum Hered</source><year>2001</year><volume>52</volume><fpage>116</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">11512557</pub-id><pub-id pub-id-type="doi">10.1159/000053364</pub-id></citation></ref><ref id="B15"><citation citation-type="other"><article-title>The GDB Human Genome Database</article-title><ext-link ext-link-type="uri" xlink:href="http://www.gdb.org"/></citation></ref><ref id="B16"><citation citation-type="other"><article-title>Ensembl Genome Browser</article-title><ext-link ext-link-type="uri" xlink:href="http://www.ensembl.org"/></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meindl</surname><given-names>A</given-names></name></person-group><article-title>German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><fpage>472</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">11802209</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1626</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cortesi</surname><given-names>L</given-names></name><name><surname>Turchetti</surname><given-names>D</given-names></name><name><surname>Bertoni</surname><given-names>C</given-names></name><name><surname>Zanocco-Marani</surname><given-names>T</given-names></name><name><surname>Vinceti</surname><given-names>M</given-names></name><name><surname>Silvestri</surname><given-names>C</given-names></name><name><surname>Federico</surname><given-names>M</given-names></name><name><surname>Silingardi</surname><given-names>V</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name></person-group><article-title>Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes</article-title><source>Eur J Hum Genet</source><year>2003</year><volume>11</volume><fpage>210</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12673274</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5200948</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Carothers</surname><given-names>AD</given-names></name><name><surname>Pirastu</surname><given-names>M</given-names></name></person-group><article-title>Population choice in mapping genes for complex diseases</article-title><source>Nat Genet</source><year>1999</year><volume>23</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">10581024</pub-id><pub-id pub-id-type="doi">10.1038/70501</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casula</surname><given-names>M</given-names></name><name><surname>Colombino</surname><given-names>M</given-names></name><name><surname>Satta</surname><given-names>MP</given-names></name><name><surname>Cossu</surname><given-names>A</given-names></name><name><surname>Lissia</surname><given-names>A</given-names></name><name><surname>Budroni</surname><given-names>M</given-names></name><name><surname>Simeone</surname><given-names>E</given-names></name><name><surname>Calemma</surname><given-names>R</given-names></name><name><surname>Loddo</surname><given-names>C</given-names></name><name><surname>Caraco</surname><given-names>C</given-names></name><name><surname>Mozzillo</surname><given-names>N</given-names></name><name><surname>Daponte</surname><given-names>A</given-names></name><name><surname>Comella</surname><given-names>G</given-names></name><name><surname>Canzanella</surname><given-names>S</given-names></name><name><surname>Guida</surname><given-names>M</given-names></name><name><surname>Castello</surname><given-names>G</given-names></name><name><surname>Ascierto</surname><given-names>PA</given-names></name><name><surname>Palmieri</surname><given-names>G</given-names></name></person-group><article-title>Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy</article-title><source>Eur J Cancer</source><year>2007</year><volume>43</volume><fpage>137</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">17055252</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2006.07.017</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tonin</surname><given-names>P</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Offit</surname><given-names>K</given-names></name><name><surname>Couch</surname><given-names>F</given-names></name><name><surname>Rebbeck</surname><given-names>TR</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Wagner-Costalos</surname><given-names>J</given-names></name><name><surname>Berman</surname><given-names>D</given-names></name><name><surname>Grana</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>E</given-names></name><name><surname>Kane</surname><given-names>MF</given-names></name><name><surname>Kolodner</surname><given-names>RD</given-names></name><name><surname>Krainer</surname><given-names>M</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name><name><surname>Struewing</surname><given-names>JP</given-names></name><name><surname>Warner</surname><given-names>E</given-names></name><name><surname>Rosen</surname><given-names>B</given-names></name><name><surname>Lerman</surname><given-names>C</given-names></name><name><surname>Peshkin</surname><given-names>B</given-names></name><name><surname>Norton</surname><given-names>L</given-names></name><name><surname>Serova</surname><given-names>O</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name></person-group><article-title>Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families</article-title><source>Nat Med</source><year>1996</year><volume>2</volume><fpage>1179</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8898735</pub-id><pub-id pub-id-type="doi">10.1038/nm1196-1179</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Olafsdottir</surname><given-names>G</given-names></name><name><surname>Tryggvadottir</surname><given-names>L</given-names></name><name><surname>Neuhausen</surname><given-names>S</given-names></name><name><surname>Jonasson</surname><given-names>JG</given-names></name><name><surname>Tavtigian</surname><given-names>SV</given-names></name><name><surname>Tulinius</surname><given-names>H</given-names></name><name><surname>Ogmundsdottir</surname><given-names>HM</given-names></name><name><surname>Eyfjord</surname><given-names>JE</given-names></name></person-group><article-title>A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes</article-title><source>Nat Genet</source><year>1996</year><volume>13</volume><fpage>117</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8673089</pub-id><pub-id pub-id-type="doi">10.1038/ng0596-117</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>E</given-names></name><name><surname>Foulkes</surname><given-names>W</given-names></name><name><surname>Goodwin</surname><given-names>P</given-names></name><name><surname>Meschino</surname><given-names>W</given-names></name><name><surname>Blondal</surname><given-names>J</given-names></name><name><surname>Paterson</surname><given-names>C</given-names></name><name><surname>Ozcelik</surname><given-names>H</given-names></name><name><surname>Goss</surname><given-names>P</given-names></name><name><surname>Allingham-Hawkins</surname><given-names>D</given-names></name><name><surname>Hamel</surname><given-names>N</given-names></name></person-group><article-title>Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer</article-title><source>J Natl Cancer Inst</source><year>1999</year><volume>91</volume><fpage>1241</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10413426</pub-id><pub-id pub-id-type="doi">10.1093/jnci/91.14.1241</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gershoni-Baruch</surname><given-names>R</given-names></name><name><surname>Dagan</surname><given-names>E</given-names></name><name><surname>Fried</surname><given-names>G</given-names></name><name><surname>Bruchim Bar-Sade</surname><given-names>R</given-names></name><name><surname>Sverdlov-Shiri</surname><given-names>R</given-names></name><name><surname>Zelicksson</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name></person-group><article-title>Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>983</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10885601</pub-id><pub-id pub-id-type="doi">10.1016/S0959-8049(00)00045-9</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johannesdottir</surname><given-names>G</given-names></name><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Bergthorsson</surname><given-names>JT</given-names></name><name><surname>Arason</surname><given-names>A</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Eiriksdottir</surname><given-names>G</given-names></name><name><surname>Johannsson</surname><given-names>OT</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Ingvarsson</surname><given-names>S</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Egilsson</surname><given-names>V</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name></person-group><article-title>High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>3663</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8706004</pub-id></citation></ref></ref-list></back></article> 